<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00456118</url>
  </required_header>
  <id_info>
    <org_study_id>I06014</org_study_id>
    <nct_id>NCT00456118</nct_id>
  </id_info>
  <brief_title>Study of the Role of Tissular Maternofetal Alloimmunization in Placentation Pathologies</brief_title>
  <official_title>Study of the Role of Tissular Maternofetal Alloimmunization in Placentation Pathologies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Limoges</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Limoges</source>
  <brief_summary>
    <textblock>
      Justification:

      We have recently demonstrated that maternofetal alloimmunization was not limited to blood
      cells: maternal alloimmunization against a glomerular podocyte antigen expressed by the
      placenta can induce neonatal membranous glomerulonephritis.

      Early recurrent pregnancy losses, preeclampsia and intervillositis are obstetrical
      pathologies which share an anomaly of placentation. Pathophysiology of these diseases is not
      yet fully understood; nevertheless the hypothesis of an incompatibility between mother and
      child is often mentioned. The aim of this project is to detect and study the cases of
      recurrent pregnancy losses, preeclamspia and intervillositis which could be induced by
      tissular maternofetal alloimmunization.

      Materials and methods:

      Patients suffering from recurrent pregnancy losses of unknown origin, preeclamspia or
      intervillositis will be included in this project. Mothers' sera will be studied by indirect
      immunofluorescence and Western Blot on placental biopsies from different origins and
      gestational ages. This stage will enable us to detect possible maternal allo-antibodies.
      After detecting and revealing antibodies, nature of the target antigen will be identified by
      immunoprecipitation of placental extracts, using the positive sera. Immunoprecipitation will
      be followed by a mass spectrometry analysis of detected proteins.

      Expected results:

      This study will enable us:

        -  to detect new cases of tissular maternofetal alloimmunization

        -  to improve our knowledge of mechanisms leading to anomalies of placentation

        -  to carry out a specific, preventive therapeutic approach for cases induced by tissular
           alloimmunization.

      Key words:

      Recurrent pregnancy losses, Preeclampsia, Intervillositis, maternofetal alloimmunization.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2006</start_date>
  <completion_date type="Actual">December 2009</completion_date>
  <primary_completion_date type="Actual">July 2009</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Actual">83</enrollment>
  <condition>Recurrent Pregnancy Losses</condition>
  <condition>Preeclampsia</condition>
  <condition>Intervillositis</condition>
  <arm_group>
    <arm_group_label>repeated miscarriages</arm_group_label>
    <description>60 womens for repeated miscarriages will be included</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Preeclampsia</arm_group_label>
    <description>70 women for pre-eclampsia will be included</description>
  </arm_group>
  <arm_group>
    <arm_group_label>intervillites</arm_group_label>
    <description>20 women for intervillites will be included</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Neonatal pathologies can be caused by an alloimmunisation maternal fetal tissue, it's
        conceivable that certain pathologies. Obstetrics may be part of the same mechanism. Among
        these pathologies placentaires, for whom a &quot;maternal-fetal incompatibility&quot; is often
        mentioned, could be secondary to tissue alloimmunization against antigens independent of
        the immune system
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Recurrent pregnancy losses : patient having or having suffered from at least 3
             consecutive, unexplained recurrent pregnancy losses, during the first 3 months of
             pregnancy, with the same paerson/man.

          -  Preeclampsia : blood pressure &gt; 140/90 mm Hg ; proteinuria &gt; 0,3 g/ 24 h

          -  Intervillositis : patient suffering or having suffered from intervillositis

        Exclusion Criteria:

          -  Recurrent pregnancy losses : uterine pathology, endocrine pathology, autoimmune
             pathology, coagulation and hemostasis pathology, karyotype anomaly.

          -  Preeclampsia : pre-existing high blood pressure, pre-existing diabetes, pre-existing
             renal disease, antiphospholipid antibodies syndrome

          -  Intervillositis : intervillositis with villositis
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Vincent GUIGONIS, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Limoges</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Bordeaux University Hospital</name>
      <address>
        <city>Bordeaux</city>
        <zip>33076</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>LIMOGES University Hospital</name>
      <address>
        <city>Limoges</city>
        <zip>87042</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saint Antoine Hospital</name>
      <address>
        <city>Paris</city>
        <zip>75012</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tenon Hospital</name>
      <address>
        <city>Paris</city>
        <zip>75020</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Trousseau Hospital</name>
      <address>
        <city>Paris</city>
        <zip>75571</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>South Reunion Hospital</name>
      <address>
        <city>Saint Pierre</city>
        <zip>97448</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Toulouse University Hospital</name>
      <address>
        <city>Toulouse</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>May 2009</verification_date>
  <study_first_submitted>April 3, 2007</study_first_submitted>
  <study_first_submitted_qc>April 3, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 4, 2007</study_first_posted>
  <last_update_submitted>August 10, 2018</last_update_submitted>
  <last_update_submitted_qc>August 10, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">August 13, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>recurrent pregnancy losses</keyword>
  <keyword>preeclampsia</keyword>
  <keyword>intervillositis</keyword>
  <keyword>maternofetal alloimmunization</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pre-Eclampsia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

